Payment overview · 2025
General Payments
$132,604.18
240 reported records · 13 companies
Healthcare provider profile · identity verified
William Anthony Gray, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine|Interventional Cardiology · WYNNEWOOD, PA · NPI 1720165640
Verified facts
What the public records show
CMS Open Payments records show William Anthony Gray, M.D. received $132,604.18 in general payments during 2025 across 240 reported records.
Boston Scientific Corporation accounted for 21.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 39 associated products.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $27,985.30 | 21.1% | 106 | 2025 |
| W. L. Gore & Associates, Inc. | Unresolved — no canonical attribution shown | $25,293.61 | 19.1% | 18 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$25,057.26 | 18.9% | 64 | 2025 |
| Philips North America LLC | Unresolved — no canonical attribution shown | $20,111.94 | 15.2% | 20 | 2025 |
| Edwards Lifesciences Corporation | Unresolved — no canonical attribution shown | $16,826.80 | 12.7% | 16 | 2025 |
| Shockwave Medical, Inc | Unresolved — no canonical attribution shown | $16,032.84 | 12.1% | 2 | 2025 |
| InspireMD Ltd | Unresolved — no canonical attribution shown | $448.40 | 0.3% | 5 | 2025 |
| Endologix LLC | Unresolved — no canonical attribution shown | $427.56 | 0.3% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $299.95 | 0.2% | 3 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $54.27 | 0.0% | 2 | 2025 |
| Imperative Care, Inc | Unresolved — no canonical attribution shown | $34.64 | 0.0% | 1 | 2025 |
| Terumo Medical Corporation | Unresolved — no canonical attribution shown | $17.36 | 0.0% | 1 | 2025 |
| Biosense Webster, Inc. | Unresolved — no canonical attribution shown | $14.25 | 0.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Consulting Fee | $81,680.00 | 30 |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $23,475.00 | 6 |
| Travel and Lodging | $19,931.00 | 39 |
| Food and Beverage | $7,518.18 | 165 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| GORE VIABAHN Endoprosthesis Normalized: gore viabahn endoprosthesis |
Device | W. L. Gore & Associates, Inc. | $18,760.00 | 2 | 2025 |
Source payment records
|
|||||
| GORE VIABAHN Endoprosthesis with Heparin Normalized: gore viabahn endoprosthesis with heparin |
Device | W. L. Gore & Associates, Inc. | $18,760.00 | 2 | 2025 |
Source payment records
|
|||||
| GORE-TEX Vascular Graft Normalized: gore tex vascular graft |
Device | W. L. Gore & Associates, Inc. | $18,760.00 | 2 | 2025 |
Source payment records
|
|||||
| VIATORR Endoprosthesis Normalized: viatorr endoprosthesis |
Device | W. L. Gore & Associates, Inc. | $18,760.00 | 2 | 2025 |
Source payment records
|
|||||
| Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter Normalized: shockwave ivl system with the shockwave c2 coronary ivl catheter |
Device | Shockwave Medical, Inc | $16,032.84 | 2 | 2025 |
Source payment records
|
|||||
| GORE PROPATEN Vascular Graft Normalized: gore propaten vascular graft |
Device | W. L. Gore & Associates, Inc. | $14,740.00 | 1 | 2025 |
Source payment records
|
|||||
| General - Therapies Normalized: general therapies |
Device | Boston Scientific Corporation | $13,878.77 | 9 | 2025 |
Source payment records
|
|||||
| Peripheral Vascular Undivided Normalized: peripheral vascular undivided |
Device | Philips North America LLC | $11,218.53 | 5 | 2025 |
Source payment records
|
|||||
| AngioJet Ultra 5000A Normalized: angiojet ultra 5000a |
Device | Boston Scientific Corporation | $10,688.00 | 4 | 2025 |
Source payment records
|
|||||
| IGT Devices Undivided Normalized: igt devices undivided |
Device | Philips North America LLC | $8,773.56 | 14 | 2025 |
Source payment records
|
|||||
| PASCAL Normalized: pascal |
Device | Edwards Lifesciences Corporation | $4,446.60 | 3 | 2025 |
Source payment records
|
|||||
| VIABAHN Endoprosthesis with PROPATEN Bioactive Surface Normalized: viabahn endoprosthesis with propaten bioactive surface |
Device | W. L. Gore & Associates, Inc. | $4,020.00 | 1 | 2025 |
Source payment records
|
|||||
| GORE VIABAHN VBX Balloon Expandable Endo Normalized: gore viabahn vbx balloon expandable endo |
Device | W. L. Gore & Associates, Inc. | $3,459.96 | 11 | 2025 |
Source payment records
|
|||||
| Product in Development Normalized: product in development |
Device | W. L. Gore & Associates, Inc. | $3,010.00 | 4 | 2025 |
Source payment records
|
|||||
| General - Vascular Intervention Normalized: general vascular intervention |
Device | Boston Scientific Corporation | $2,895.10 | 17 | 2025 |
Source payment records
|
|||||
| MO.MA ULTRA Normalized: mo ma ultra |
Device | Medtronic, Inc. | $2,589.28 | 17 | 2025 |
Source payment records
|
|||||
| COREVALVE EVOLUT R Normalized: corevalve evolut r |
Device | Medtronic, Inc. | $1,329.10 | 19 | 2025 |
Source payment records
|
|||||
| CGuard Prime Carotid Stent System Normalized: cguard prime carotid stent system |
Device | InspireMD Ltd | $448.40 | 5 | 2025 |
Source payment records
|
|||||
| AVVIGO Guidance System Normalized: avvigo guidance system |
Device | Boston Scientific Corporation | $265.75 | 64 | 2025 |
Source payment records
|
|||||
| COROFLOW Normalized: coroflow |
Device | Abbott Laboratories | $170.29 | 1 | 2025 |
Source payment records
|
|||||
| SYMPLICITY G3 Normalized: symplicity g3 |
Device | Medtronic, Inc. | $148.88 | 1 | 2025 |
Source payment records
|
|||||
| Labosys Normalized: labosys |
Device | Philips North America LLC | $119.85 | 1 | 2025 |
Source payment records
|
|||||
| ESPRIT Normalized: esprit |
Device | Abbott Laboratories | $115.85 | 1 | 2025 |
Source payment records
|
|||||
| FARAPULSE Normalized: farapulse |
Device | Boston Scientific Corporation | $80.77 | 4 | 2025 |
Source payment records
|
|||||
| GORE EXCLUDER Thoracoabdominal Branch Endoprosthesis Normalized: gore excluder thoracoabdominal branch endoprosthesis |
Device | W. L. Gore & Associates, Inc. | $63.65 | 1 | 2025 |
Source payment records
|
|||||
| ACCOLADE SR Normalized: accolade sr |
Device | Boston Scientific Corporation | $61.00 | 1 | 2025 |
Source payment records
|
|||||
| ELUVIA Normalized: eluvia |
Device | Boston Scientific Corporation | $37.90 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $35.00 | 1 | 2025 |
Source payment records
|
|||||
| SEISMIQ Prime Catheter_PI Normalized: seismiq prime catheter pi |
Device | Boston Scientific Corporation | $34.94 | 1 | 2025 |
Source payment records
|
|||||
| SYMPHONY CATHETER Normalized: symphony catheter |
Device | Imperative Care, Inc | $34.64 | 1 | 2025 |
Source payment records
|
|||||
| General - Metallic Stents Normalized: general metallic stents |
Device | Boston Scientific Corporation | $34.07 | 2 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $19.27 | 1 | 2025 |
Source payment records
|
|||||
| EVOQUE Normalized: evoque |
Device | Edwards Lifesciences Corporation | $17.84 | 1 | 2025 |
Source payment records
|
|||||
| ANGIO-SEAL Normalized: angio seal |
Device | Terumo Medical Corporation | $17.36 | 1 | 2025 |
Source payment records
|
|||||
| METACROSS OTW Normalized: metacross otw |
Device | Terumo Medical Corporation | $17.36 | 1 | 2025 |
Source payment records
|
|||||
| TR BAND Normalized: tr band |
Device | Terumo Medical Corporation | $17.36 | 1 | 2025 |
Source payment records
|
|||||
| QDOT MICRO Normalized: qdot micro |
Device | Biosense Webster, Inc. | $14.25 | 1 | 2025 |
Source payment records
|
|||||
| MITRACLIP Normalized: mitraclip |
Device | Abbott Laboratories | $13.81 | 1 | 2025 |
Source payment records
|
|||||
| ROTAPRO Normalized: rotapro |
Device | Boston Scientific Corporation | $9.00 | 3 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
No publishable same-company prescribing overlap was found in the loaded Part D year. This does not mean the doctor never prescribed a drug reported elsewhere by a paying company.
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Amlodipine Besylate | Amlodipine Besylate | 21 | suppressed |
| Atorvastatin Calcium | Atorvastatin Calcium | 17 | suppressed |
| Losartan Potassium | Losartan Potassium | 13 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 12 | suppressed |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $132,604.18 · 240 records | Boston Scientific Corporation | ACCOLADE SR, ANGIO-SEAL, AVVIGO Guidance System, AngioJet Ultra 5000A, CGuard Prime Carotid Stent System, COREVALVE EVOLUT R, COROFLOW, ELUVIA, ESPRIT, EVOQUE, FARAPULSE, GORE EXCLUDER Thoracoabdominal Branch Endoprosthesis, GORE PROPATEN Vascular Graft, GORE VIABAHN Endoprosthesis, GORE VIABAHN Endoprosthesis with Heparin, GORE VIABAHN VBX Balloon Expandable Endo, GORE-TEX Vascular Graft, General - Metallic Stents, General - Therapies, General - Vascular Intervention, IGT Devices Undivided, Labosys, METACROSS OTW, MITRACLIP, MO.MA ULTRA, Ozempic, PASCAL, Peripheral Vascular Undivided, Product in Development, QDOT MICRO, ROTAPRO, SEISMIQ Prime Catheter_PI, SYMPHONY CATHETER, SYMPLICITY G3, Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter, TR BAND, VIABAHN Endoprosthesis with PROPATEN Bioactive Surface, VIATORR Endoprosthesis, Wegovy | — | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error